Compositions comprising an anti-c5 antibody

Abstract

The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.

1 - 30 . (canceled) 
     
     
         31 . A pharmaceutical composition comprising an anti-C5 antibody, sodium phosphate, sodium chloride, and polysorbate 80, wherein the anti-C5 antibody comprises a variable light chain CDR1 comprising amino acid residues 26-36 of SEQ ID NO:1, a variable light chain CDR2 comprising amino acid residues 52-58 of SEQ ID NO:1, a variable light chain CDR3 comprising amino acid residues 91-99 of SEQ ID NO:1, a variable heavy chain CDR1 comprising amino acid residues 152-161 of SEQ ID NO:1, a variable heavy chain CDR2 comprising amino acid residues 176-192 of SEQ ID NO:1, and a variable heavy chain CDR3 comprising amino acid residues 225-237 of SEQ ID NO:1. 
     
     
         32 . The pharmaceutical composition of  claim 31 , wherein the pH of the composition is between pH 6 and pH 8. 
     
     
         33 . The pharmaceutical composition of  claim 32 , wherein the composition has physiologic osmolality. 
     
     
         34 . A pharmaceutical composition comprising an anti-C5 antibody, sodium phosphate, sodium chloride, and polysorbate 80, wherein the anti-C5 antibody comprises a heavy chain variable region comprising residue numbers 1-122 of SEQ ID NO: 2 and a light chain variable region comprising residue numbers 1-108 of SEQ ID NO: 3. 
     
     
         35 . The pharmaceutical composition of  claim 34 , wherein the pH of the composition is between pH 6 and pH 8. 
     
     
         36 . The pharmaceutical composition of  claim 35 , wherein the composition has physiologic osmolality. 
     
     
         37 . A pharmaceutical composition comprising between 1 and 30 mg/mL of an anti-C5 antibody, sodium phosphate, sodium chloride, and polysorbate 80, wherein the anti-C5 antibody comprises a variable light chain CDR1 comprising amino acid residues 26-36 of SEQ ID NO:1, a variable light chain CDR2 comprising amino acid residues 52-58 of SEQ ID NO:1, a variable light chain CDR3 comprising amino acid residues 91-99 of SEQ ID NO:1, a variable heavy chain CDR1 comprising amino acid residues 152-161 of SEQ ID NO:1, a variable heavy chain CDR2 comprising amino acid residues 176-192 of SEQ ID NO:1, and a variable heavy chain CDR3 comprising amino acid residues 225-237 of SEQ ID NO:1. 
     
     
         38 . The pharmaceutical composition of  claim 37 , wherein the pH of the composition is between pH 6 and pH 8. 
     
     
         39 . The pharmaceutical composition of  claim 38 , wherein the composition has physiologic osmolality. 
     
     
         40 . A pharmaceutical composition comprising between 1 and 30 mg/mL of an anti-C5 antibody, sodium phosphate, sodium chloride, and polysorbate 80, wherein the anti-C5 antibody comprises a heavy chain variable region comprising residue numbers 1-122 of SEQ ID NO: 2 and a light chain variable region comprising residue numbers 1-108 of SEQ ID NO: 3. 
     
     
         41 . The pharmaceutical composition of  claim 40 , wherein the pH of the composition is between pH 6 and pH 8. 
     
     
         42 . The pharmaceutical composition of  claim 41 , wherein the composition has physiologic osmolality.